

## **ASX** Release

Sigma Healthcare Limited

ABN 15 088 417 403 ASX code: SIG

Level 6, 2125 Dandenong Road Clayton VIC 3168 Australia

T 1800 500 760 T +61 (03) 9215 9215 F +61 (03) 9215 9188

sigmahealthcare.com.au

6 October 2023

## Sigma Healthcare Limited Continues Board Renewal, Announces Changes to Non-Executive Directors

- Appointment of Dr. Chris Roberts as a nominee of Sigma's ~19% shareholder HMC Capital, reflecting HMC Capital's significant investment in and ongoing support for Sigma
- Resignation of Ms Christine Bartlett, following seven years of service as a Non-Executive Director
- Continued Board renewal positions Sigma to deliver on its strategy and growth ambitions

Sigma Healthcare Limited (Sigma) announces the following changes to the composition of the Board. The appointment will be presented for approval of shareholders at the Annual General Meeting of Sigma scheduled to be held in May 2024.

## Appointment: Dr. Chris Roberts AO

Dr. Roberts will be appointed a Non-Executive Director of Sigma effective 6 October 2023

Dr. Roberts has more than 40 years' experience in the medical device industry, including as the former CEO of Cochlear Limited (ASX:COH) from 2004 to 2015, Executive Vice President of ResMed Inc (NYSE:RMD) from 1992 to 2003 and as a Director until November 2017. He is currently a Non-Executive Director of: HMC Capital managed HealthCo Healthcare and Wellness REIT (ASX: HCW), HMC Capital Partners Fund 1, Clarity Pharmaceuticals Limited (ASX:CU6), Nutromics Pty Ltd, Atmo Biosciences Limited and the Cochlear Foundation Board. He is also a Governor of the Centenary Institute Cancer Medicine and Cell Biology.

Dr. Roberts has been nominated by HMC Capital Partners Fund 1, a ~19% shareholder in Sigma.

Dr. Roberts will be a member of the Risk, Management & Audit Committee effective 6 October 2023.

Chairman Michael Sammells said, "The Board welcomes Chris' appointment, representing our supportive major shareholder HMC Capital. Chris brings significant healthcare industry experience, including leadership roles at two of Australia's most successful global companies and will be invaluable to the Board and Management as we continue to execute our growth strategy."

Dr. Roberts said, "I am delighted to be joining the Board of Sigma, a business with a long history and a number of exciting future growth opportunities. I look forward to working with my fellow Directors to support Vikesh and the Sigma management team in delivering success for Sigma's shareholders and customers."



## **Resignation: Ms Christine Bartlett**

Ms Christine Bartlett has advised the Board of her intention to retire as a Non-Executive Director of Sigma effective from the conclusion of the Sigma Board meeting on 7 December 2023. Christine's decision follows seven years of valuable service to Sigma and is in recognition of her increased workload following her recent appointment as a Non-Executive Director of Australian Clinical Labs Limited.

Christine was appointed a Director of Sigma in March 2016 and has chaired the Nomination and Remuneration Committee since August 2020.

Sigma Chairman Michael Sammells commented: "Christine has been a valuable and experienced contributor during her seven years on the Sigma Board. Christine played a critical role in the global search and recruitment of our CEO over 18 months ago and has provided strong leadership as a Director and in her role as Chair of the Nomination and Remuneration Committee. We thank Christine for her dedicated service and enormous contribution to Sigma."

Ms Kate Spargo, currently a member of Sigma's Nomination and Remuneration Committee, will be appointed Chair of the Nomination and Remuneration Committee following Ms Bartlett's resignation.

This announcement is authorised by order of the Company Secretary.

For more information contact

Gary Woodford Head of Corporate Affairs and Interim CFO gary.woodford@sigmahealthcare.com.au 0417 399 204 Steve Dabkowski Blue Dot Media steve@bluedot.net.au 0419 880 486